Hypertensive diseases of pregnancy (HES) affect approximately 6–8% of all pregnancies and contribute to 20–25% of perinatal mortality globally. Among these, preeclampsia represents the most severe manifestation, contributing to over 70,000 maternal and 500,000 perinatal deaths anually worldwide [1]. In July 2024, the updated S2k guidelines on hypertensive diseases during pregnancy (HES) were published, presenting updated recommendations for improved diagnosis and therapeutic strategies. Notable advancements in the revised guidelines include an emphasis on the early identification of patients at risk, implementation of individualized monitoring protocols, establishment of optimized target blood pressure thresholds, and the critical importance of long-term cardiovascular follow-up for the affected mother—ideally extending throughout the patient`s lifespan [2]. As in the previous version, the current guidelines retain a dedicated section addressing anesthesiological considerations in the peripartum period. Furthermore, they expand on the anaesthetic implications relevant to both preclinical and clinical care settings for pregnant individuals with HES. This article provides a concise synthesis of the most clinically pertinent innovations introduced in the 2024 guideline update.
